Accompanying editorial for article: GD2-CART01 for relapsed or refractory high-risk neuroblastoma
Last Updated: Monday, July 17, 2023
Authored by Drs. Oladapo O. Yeku and Dan L. Longo, this accompanying editorial to the article, “GD2-CART01 for relapsed or refractory high-risk neuroblastoma,” explains the science behind use of GD2- CAR T cells that express the inducible caspase 9 suicide gene as a therapeutic option for children and young adults with heavily pretreated neuroblastoma.
Advertisement
News & Literature Highlights